The journey to understanding incretin systems: Theory, practice and more theory

Accumulating clinical data on incretin ‐based dipeptidyl peptidase‐4 inhibitors and glucagon‐like peptide‐1 receptor agonists in the past decade have clearly confirmed their safety and efficacy as antidiabetes drugs. However, the journey to understand the incretin system and its role in health and disease continues.
Source: Journal of Diabetes Investigation - Category: Endocrinology Authors: Tags: JDI Updates Source Type: research